Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis:...

Area of Science:

• Gastroenterology
• Pharmacokinetics
• Clinical Trial Analysis

Background:

• The role of infliximab therapeutic drug monitoring in acute severe ulcerative colitis (ASUC) management remains unclear.
• Understanding infliximab levels and clearance is crucial for optimizing treatment in ASUC.

Purpose of the Study:

• To determine if infliximab therapeutic drug monitoring is associated with ASUC outcomes.
• To investigate the relationship between infliximab levels, clearance, and clinical response in ASUC patients.

Main Methods:

• Serum and stool samples were collected from patients in the PREDICT-UC randomized controlled trial.
• Infliximab levels were measured, and clearance was derived using pharmacokinetic modeling.
• Correlations between infliximab levels/clearance and ASUC outcomes were analyzed.

Main Results:

• Lower day 3 serum infliximab levels predicted treatment failure and colectomy.
• High infliximab clearance was associated with response to higher infliximab doses (10 mg/kg vs 5 mg/kg).
• Day 3 fecal infliximab levels correlated with endoscopic severity and nonresponse.

Conclusions:

• Early infliximab levels and clearance calculations can predict ASUC outcomes.
• Intensified infliximab dosing strategies can effectively manage patients with high infliximab clearance.
• This study provides evidence for the utility of therapeutic drug monitoring in ASUC.